Michael Roost Clausen

Also affiliated with Vejle Sygehus

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2”.

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2

Hematological Oncology(2023)10.1002/hon.3166_ot28

N/A

0.292DataRank · unranked

6 citations

Martine E.D. Chamuleau, Georg Lenz, Michael Roost Clausen, Corinne Haïoun, Koji Izutsu +11 more

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0.104DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more